华邦健康(002004) - 2021 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2021 was ¥2,819,567,735.13, representing a 25.05% increase compared to ¥2,254,687,980.04 in the same period last year[9] - Net profit attributable to shareholders was ¥121,602,831.86, up 46.74% from ¥82,868,734.68 year-on-year[9] - The net profit excluding non-recurring gains and losses was ¥119,913,108.96, reflecting a 53.67% increase from ¥78,033,653.00 in the previous year[9] - The basic earnings per share increased by 50.00% to ¥0.06 from ¥0.04 in the same period last year[9] - Net profit for the current period was ¥169,587,546.40, compared to ¥100,386,554.23 in the previous period, representing a growth of approximately 69%[63] - The company reported a total comprehensive income of ¥175,227,007.48 for the current period, compared to ¥121,333,970.77 in the previous period[67] - The net profit for the current period is -44,513,512.08 yuan, compared to a net profit of 210,287,845.91 yuan in the previous period, indicating a significant decline[71] - The total comprehensive income for the current period is -44,513,512.08 yuan, compared to 210,287,845.91 yuan in the previous period[75] - The basic and diluted earnings per share for the current period are both -0.02 yuan, compared to 0.11 yuan in the previous period[75] Cash Flow - The net cash flow from operating activities was negative at -¥37,804,090.99, a decline of 121.00% compared to ¥179,982,272.78 in the same period last year[9] - Cash inflow from operating activities totals 2,397,775,111.68 yuan, an increase from 2,163,279,472.36 yuan in the previous period[80] - Cash outflow from operating activities is 2,435,579,202.67 yuan, compared to 1,983,297,199.58 yuan in the previous period[80] - The net cash flow from operating activities is -37,804,090.99 yuan, a decrease from 179,982,272.78 yuan in the previous period[80] - Cash inflow from investing activities is 2,068,398,149.06 yuan, down from 2,600,016,722.22 yuan in the previous period[80] - Cash outflow from investing activities totals 2,150,236,935.36 yuan, compared to 2,998,462,472.54 yuan in the previous period[80] - The net cash flow from financing activities is 50,143,727.51 yuan, a decrease from 551,649,767.85 yuan in the previous period[82] - The ending cash and cash equivalents balance is 2,149,967,771.89 yuan, compared to 2,215,538,841.73 yuan in the previous period[82] Assets and Liabilities - The total assets at the end of the reporting period were ¥28,738,539,024.16, a 1.82% increase from ¥28,226,109,662.70 at the end of the previous year[9] - The total amount of long-term prepaid expenses decreased by 49.54% to RMB 350,581,523.69 from RMB 694,804,340.49 in the previous period[21] - The total amount of long-term payables increased by 70.14% to RMB 334,830,575.44 from RMB 196,801,465.44 in the previous period[21] - Total liabilities reached ¥14,440,258,265.55, up from ¥14,089,427,152.31, marking a growth of around 2.48%[45] - Owner's equity increased to ¥14,298,280,758.61 from ¥14,136,682,510.39, showing a growth of about 1.14%[48] - The total liabilities decreased to ¥6,810,109,810.40 from ¥7,094,570,450.54, indicating improved financial stability[55] - Owner's equity totaled ¥8,018,263,519.02, slightly down from ¥8,062,777,031.10 in the previous period[55] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 91,267[14] - The largest shareholder, Tibet Huibang Technology Co., Ltd., held 18.71% of the shares, with a total of 370,449,804 shares[14] Operational Metrics - The company reported non-recurring gains and losses totaling ¥1,689,722.90 for the reporting period[9] - The company experienced a 36.45% increase in income tax expenses, amounting to RMB 63,005,118.03 compared to RMB 46,173,974.90 in the previous period[21] - The company has established strict internal controls for foreign exchange forward settlement and risk management to mitigate operational risks[29] - The company is committed to focusing on production and sales while managing foreign exchange risks through forward contracts[29] Investment Activities - The company did not engage in any securities investments during the reporting period[25] - The total amount of derivative investments at the end of the reporting period was RMB 73,998.55, accounting for 5.18% of the company's net assets[26] - The company’s investment activities generated a net cash flow of -RMB 81,838,786.30, an improvement of 79.46% from -RMB 398,445,750.32 in the previous period[21] Research and Development - Research and development expenses were ¥73,643,518.69, a slight decrease from ¥75,496,146.72 in the previous period, indicating a focus on cost management[60] Compliance and Governance - The company has no overdue or unrecovered amounts in its entrusted financial management activities[33] - The company has no violations regarding external guarantees during the reporting period[34] - The company reported no non-operating fund occupation by controlling shareholders or related parties during the reporting period[35]